Hone Health vs MEDVi: Which GLP-1 Provider Is Better?
A side-by-side comparison of Hone Health and MEDVi covering pricing, scores, medication types, insurance, and more to help you decide.
Hone Health
#14 of 318.1/10
Comprehensive men's health platform that includes GLP-1 medications alongside hormone optimization and lab testing.
Visit Hone HealthHigher Rated
MEDVi
#9 of 318.3/10
Compounded GLP-1 platform offering both oral and injectable options with flexible dosing and affordable pricing.
Visit MEDVi| Feature | Hone Health | MEDVi |
|---|---|---|
| Our Score | 8.1/10 | 8.3/10 |
| Starting Price | $160/mo | $179/mo |
| Medication Type | Compounded | Compounded |
| Insurance Accepted | No | No |
| Best For | Users who want a full-service health platform covering weight loss plus hormones and labs | Users who want a low entry price with oral and injectable compounded options |
| Ranking | #14 | #9 |
Pros & Cons Compared
Hone Health
Pros
- +Full-service health platform
- +Lab testing included
- +Hormone optimization available
- +Comprehensive approach
Cons
- −Compounded only for GLP-1
- −More complex offering
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
Cons
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Our Verdict
MEDVi edges out Hone Health with a score of 8.3/10 vs 8.1/10. If budget is your priority, Hone Health starts at $160/mo compared to MEDVi's $179/mo. Choose Hone Health if you want: users who want a full-service health platform covering weight loss plus hormones and labs. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.